๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Chongqing 6 Shanghai 6 Hangzhou 6 Changchun 5
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Chongqing6 Shanghai6 Hangzhou6 Changchun5
All 40 locations
Target enrolment
to

Trials with a site in Shanghai

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Changsha, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan
2026-04-22
Recruiting
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
NCT07455734Advanced Solid Tumor Cancer
BioNTech SE
Phase 1/2
533
Chongqing, Guangzhou, Hangzhou, Shanghai, Tianjin
2026-03-30
Recruiting
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT07297212Recurrent Glioblastoma
BioNTech SE
Phase 2
75
Beijing, Chongqing, Jinan, Shanghai, Shenzhen, Wuhan
2026-01-15
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Changchun, Hangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-01-07
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

6 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 6 studies
PhaseStudiesRecruitingShare
Phase 1/23350%
Phase 21116.7%
Phase 2/31116.7%
Phase 31116.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
BioNTech SE66
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.